Technology enables diagnostic and therapeutic applications in a single procedure based on an expandable tip, two-working channels in 2mm working diameter

DENVER--(BUSINESS WIRE)--enlightenVue�, Inc. announced today that China has granted the company a patent covering the core technology underlying its surgiVue� single-use micro-endoscope platform. The patented technology enables the endoscope for diagnostic and therapeutic applications in a single procedure through two working channels in a two-millimeter working diameter.

�The patent covers the key innovation in our micro-endoscope, an expandable tip that provides access for multiple instruments within the industry�s smallest working diameter, along with superior optics,� said Giacomo Basadonna, M.D., Ph.D. �The endoscope�s dual functionality, along with the small working channel, allows its use in a wide range of applications with no patient cross-contamination risk.�

The platform�s potential, based on its small diameter size, extends to novel applications that have not been accessible to other endoscopes and conventional endoscopy applications such as hepatobiliary; ear, nose and throat; obstetrics and gynecology; and orthopedics. In addition, the endoscope also has potential utility in percutaneous and intra-surgical settings.

The enlightenVue technology is protected by three patent families. In addition, to the Chinese patent, there are four issued U.S. patents, including the core patent, with additional U.S. and international patents pending.

About enlightenVue

enlightenVue has developed a novel single-use micro-endoscope platform with the industry�s smallest diameter (2mm) with multiple working channels, which can be used in a single procedure for both diagnostic and therapeutic interventions. The surgiVue� platform�s dual functionality is based on a patented, expandable tip to provide access for multiple instruments along with superior optics. The system, which has 510(k) clearance, enables use across multiple specialties and healthcare settings to provide significant benefits to patients, clinicians, and the healthcare system with no cross-patient risk of endoscopic infection. Learn more at enlightenVue.com.

Contacts

Robert Gottlieb

RMG Associates, LLC

[email protected]